drugset
drugset / Trial / NCT00259649

Prospective Survey of Menstrual Migraine & Prevention With Eletriptan

NCT00259649 ↗

Phase 4 Completed 71 enrolled University of Pittsburgh Pfizer · collab
Non-randomizedSingle-groupOpen-labelPrevention

Summary

Women are followed prospectively for 3 months, recording headaches, other symptoms, and menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan for 3 months.

Timeline

Start
2004-08
Primary completion
2008-08
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Eletriptan Small molecule 20 mg Oral

Indications

migraine disorder